CO018 | THE MOLI-SANI RISK SCORE, A MEASURE OF MODIFIABLE CARDIOVASCULAR RISK, PREDICTS NON-CARDIOVASCULAR MORTALITY AND SELECTED CANCERS, BUT NOT NEURODEGENERATIVE DISEASES
Abstract
Background and aims. The Moli-sani Risk Score (MRS) is a weighted score developed in the Moli-sani Study to quantify the overall burden of modifiable cardiovascular risk by combining 9 modifiable factors, including smoking, adherence to the Mediterranean diet, blood lipids (triglycerides, LDL, and HDL-cholesterol), blood pressure, glucose, adiposity, and physical activity. Although originally developed for cardiovascular disease (CVD), it is unclear whether this measure of global modifiable CVD risk may also identify susceptibility to major non-CVD outcomes. We therefore examined the association of the MRS with mortality, hospitalization, cancer, and neurodegenerative outcomes in the Moli-sani cohort. Methods. We analyzed 16,621 men and women aged ≥45 years from the adult general population-based Moli-sani Study. Median follow-up ranged from 12 to 15 years across outcomes. Outcomes included all-cause, CVD, cancer, and other-cause mortality; all-cause hospitalization; CVD, coronary heart disease (CHD), stroke, and diabetes; breast, colorectal, lung, prostate, and renal cancer; and Alzheimer’s disease, non-Alzheimer's dementia, and Parkinson’s disease. Participants with the corresponding condition at baseline were excluded from each specific analysis. Competing risks were handled within outcome macro-areas by censoring at the first competing event in the same domain, and cause-specific Cox models were used. For interpretability, the MRS was originally rescaled so that 1 MRS point corresponds approximately to the cardiovascular risk associated with 1 additional year of age. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for a 5-point increase in MRS, that is, for an increment slightly smaller than 1 SD in our analytic sample. Results. As shown in the figure, higher MRS was associated with all-cause mortality (HR 1.18; 95% CI 1.14–1.21; Figure), cancer mortality (1.18; 1.13–1.24), other-cause mortality (1.12; 1.06–1.19), and all-cause hospitalization (1.06; 1.04–1.07). Among site-specific cancers, associations emerged for lung cancer (1.42; 1.28–1.57) and renal cancer (1.20; 1.02–1.41), but not for breast (1.03; 0.93–1.15), colorectal (1.02; 0.94–1.11), or prostate cancer (1.00; 0.92–1.08). No association was observed with neurodegenerative disorders, including Alzheimer’s disease, non-Alzheimer's dementia, and Parkinson’s disease (Figure). As expected for a score designed to capture global modifiable cardiovascular risk, MRS was also associated with CVD mortality (1.23; 1.17–1.29), CVD incidence (1.39; 1.33–1.44), CHD (1.48; 1.41–1.55), stroke (1.17; 1.08–1.27), and type 2 diabetes (1.57; 1.51–1.62). Sex-stratified analyses showed broadly similar findings in men and women. Conclusions. In this large general-population cohort, the MRS, a score of modifiable factors contributing to cardiovascular risk, was associated not only with cardiovascular outcomes but also with non-CVD mortality, all-cause hospitalization, and selected cancers. By contrast, no association emerged with neurodegenerative diseases. These findings suggest that the MRS captures a broader modifiable risk profile extending beyond CVD, although not across all non-CVD clinical outcomes.
Related
- Immunosenescence as a modifiable driver of neurodegenerative diseases: Pathways and multidimensional emerging strategies for Alzheimer's and Parkinson's diseases.
- Beyond Prognosis: A Systematic Review of the Neutrophil-to-Lymphocyte Ratio as a Modifiable Cardiovascular Biomarker
- Modifiable Cardiovascular Risk Factors and Hemorrhagic Presentation in Dural Arteriovenous Fistulas: A Systematic Review With Exploratory Quantitative Synthesis
- Trends in Modifiable Risk Factors Contributing to Ischemic Heart Disease Mortality in Afghanistan: Estimates From the Global Burden of Disease Study 2023 (1999-2023)
- Absence of Documented Standard Modifiable Cardiovascular Risk Factors Among Catheterized Admissions in Bangladesh: Frequency and Coronary Angiographic Phenotype in a 20‐Year Registry Study
BibTeX
@article{bracone2026co018,
title = {{CO018 | THE MOLI-SANI RISK SCORE, A MEASURE OF MODIFIABLE CARDIOVASCULAR RISK, PREDICTS NON-CARDIOVASCULAR MORTALITY AND SELECTED CANCERS, BUT NOT NEURODEGENERATIVE DISEASES}},
author = {Francesca Bracone},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/720},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO018 | THE MOLI-SANI RISK SCORE, A MEASURE OF MODIFIABLE CARDIOVASCULAR RISK, PREDICTS NON-CARDIOVASCULAR MORTALITY AND SELECTED CANCERS, BUT NOT NEURODEGENERATIVE DISEASES
AU - Francesca Bracone
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/720
AB - Background and aims. The Moli-sani Risk Score (MRS) is a weighted score developed in the Moli-sani Study to quantify the overall burden of modifiable cardiovascular risk by combining 9 modifiable factors, including smoking, adherence to the Mediterranean diet, blood lipids (triglycerides, LDL, and HDL-cholesterol), blood pressure, glucose, adiposity, and physical activity. Although originally developed for cardiovascular disease (CVD), it is unclear whether this measure of global modifiable CVD risk may also identify susceptibility to major non-CVD outcomes. We therefore examined the association of the MRS with mortality, hospitalization, cancer, and neurodegenerative outcomes in the Moli-sani cohort. Methods. We analyzed 16,621 men and women aged ≥45 years from the adult general population-based Moli-sani Study. Median follow-up ranged from 12 to 15 years across outcomes. Outcomes included all-cause, CVD, cancer, and other-cause mortality; all-cause hospitalization; CVD, coronary heart disease (CHD), stroke, and diabetes; breast, colorectal, lung, prostate, and renal cancer; and Alzheimer’s disease, non-Alzheimer's dementia, and Parkinson’s disease. Participants with the corresponding condition at baseline were excluded from each specific analysis. Competing risks were handled within outcome macro-areas by censoring at the first competing event in the same domain, and cause-specific Cox models were used. For interpretability, the MRS was originally rescaled so that 1 MRS point corresponds approximately to the cardiovascular risk associated with 1 additional year of age. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for a 5-point increase in MRS, that is, for an increment slightly smaller than 1 SD in our analytic sample. Results. As shown in the figure, higher MRS was associated with all-cause mortality (HR 1.18; 95% CI 1.14–1.21; Figure), cancer mortality (1.18; 1.13–1.24), other-cause mortality (1.12; 1.06–1.19), and all-cause hospitalization (1.06; 1.04–1.07). Among site-specific cancers, associations emerged for lung cancer (1.42; 1.28–1.57) and renal cancer (1.20; 1.02–1.41), but not for breast (1.03; 0.93–1.15), colorectal (1.02; 0.94–1.11), or prostate cancer (1.00; 0.92–1.08). No association was observed with neurodegenerative disorders, including Alzheimer’s disease, non-Alzheimer's dementia, and Parkinson’s disease (Figure). As expected for a score designed to capture global modifiable cardiovascular risk, MRS was also associated with CVD mortality (1.23; 1.17–1.29), CVD incidence (1.39; 1.33–1.44), CHD (1.48; 1.41–1.55), stroke (1.17; 1.08–1.27), and type 2 diabetes (1.57; 1.51–1.62). Sex-stratified analyses showed broadly similar findings in men and women. Conclusions. In this large general-population cohort, the MRS, a score of modifiable factors contributing to cardiovascular risk, was associated not only with cardiovascular outcomes but also with non-CVD mortality, all-cause hospitalization, and selected cancers. By contrast, no association emerged with neurodegenerative diseases. These findings suggest that the MRS captures a broader modifiable risk profile extending beyond CVD, although not across all non-CVD clinical outcomes.
SN - 2785-5309
ER -